Last updated on November 2018

A Pharmacokinetic Study: Ranibizumab Aflibercept and the Effect of Vitrectomy.

Brief description of study

To study the effect of pars plana vitrectomy on the intravitreal pharmacokinetics of ranibizumab and to compare the half-life of ranibizumab and aflibercept.

Detailed Study Description

This study is a prospective, pharmacokinetic study comparing ranibizumab clearance in two groups of patients; those with and without prior vitrectomy. Additionally it will compare ranibizumab clearance to aflibercept clearance as well as the effect on systemic circulating inflammatory and safety markers. Patients will already be receiving ranibizumab or aflibercept therapy - the injection is itself administered irrespective of their participation in this study and therefore this study will not alter medical management or the choice of therapy.

To estimate ranibizumab and aflibercept clearance, it is important to measure serum concentrations at several intervals within the first 24 hours. Participants will ideally have venous blood sampling at the following times after their ranibizumab or aflibercept

  • 1 hour
  • 2 hours
  • 3 hours
  • 4 hours
  • 6 hours
  • 24 hours
  • 2 days
  • 4 days
  • 1 week*
  • 2 weeks
  • 4 weeks*

Clinical Study Identifier: NCT02174211

Contact Investigators or Research Sites near you

Start Over

Timothy L Jackson, PhD,FRCOphth

King's College Hospital NHS Foundation Trust
London, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.